Skip to main content
. 2020 Oct 14;9(10):e1193. doi: 10.1002/cti2.1193

Figure 5.

Figure 5

CMV infection is not associated with frailty, but is related to prevalence of cardiovascular disease. (a) Comparison of frailty index score between CMV‐ (n = 110), short‐term (ST) CMV+ (n = 18) and long‐term (LT) CMV+ (n = 132) participants with available frailty index score data at time point T6. (b, c) The relation of frailty with (b) the duration of CMV infection (n = 18) and (c) age of seroconversion in ST CMV+ individuals (seroconverted before frailty index score assessment, n = 16). (d, e) Relationships are shown, respectively, between frailty and CMV‐specific antibody levels at study endpoint (d) and between frailty and fold change in CMV‐specific antibody levels over 26 years (e). (f, g) Difference in increase in frailty index between CMV‐ participants (n = 110) and those who seroconverted recently after measurement point T5 (n = 4) (f) and between women aged 60–65 years that were CMV‐ (n = 11) or converted recently after T5 (n = 3) (g). Increase in frailty index: difference between frailty index as measured between T5 and T6. (h, i) Comparison of cardiovascular disease (CVD) prevalence with CMV‐specific antibody levels (h) and fold change in 25 years (i) in these antibody levels in individuals that were CMV+ at study endpoint (n = 165) (Prevalence of CVD is indicated in Table 2). Boxplots show median with interquartile range.